Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion type Assertion NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_head.
- NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion description "[STS growth and metastasis can be interrupted by combined low-dose doxorubicin and anti-VEGFR2, a strategy that attacks STS-associated endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_provenance.
- NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion evidence source_evidence_literature NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_provenance.
- NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion SIO_000772 16951193 NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_provenance.
- NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion wasDerivedFrom befree-2016 NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_provenance.
- NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_assertion wasGeneratedBy ECO_0000203 NP567504.RAjVlZhMrrCwlMzwKrv_UdwcChtw8mI-N-ps7BDTjB2vs130_provenance.